Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.59 |
| ▸ | AXL | P30530 | 2/20 | 0.57 |
| ▸ | TTK | P33981 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.52 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 3/20 | 0.51 |
| ▸ | BTK | Q06187 | 3/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027137 | 0.93 | AXL (0.63) | EGFRAXLTTKPTK2PAK1 | |
| SCHEMBL3025177 | 0.85 | EGFR (0.61) | EGFRAXLTTKPTK2PAK1 | |
| SCHEMBL3029413 | 0.84 | AXL (0.75) | EGFRAXLTTKPTK2PAK1 | |
| SCHEMBL3027514 | 0.82 | BRD4 (0.51) | EGFRAXLPTK2PAK1JAK2 | |
| SCHEMBL3024528 | 0.82 | JAK2 (0.65) | EGFRAXLTTKPTK2JAK2 | |
| SCHEMBL3022894 | 0.82 | AXL (0.51) | EGFRAXLTTKPTK2PAK1 | |
| SCHEMBL13213060 | 0.80 | AXL (0.73) | EGFRAXLPAK1JAK2BTK | |
| SCHEMBL13213064 | 0.80 | EGFR (0.59) | EGFRAXLTTKPTK2JAK2 | |
| SCHEMBL13213032 | 0.78 | AXL (0.79) | EGFRAXLPAK1JAK2BTK | |
| SCHEMBL3025164 | 0.78 | AXL (0.66) | EGFRAXLTTKPTK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393814-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SuperGen, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010090764-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010090764-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | AXL, FLT3, TYRO3 | EGFR 83/4885AXL 1/4885TTK 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.